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To the Editor:
Maes and colleagues present data from lung tissue which showed that mRNA expression for 
angiotensin converting enzyme 2 (ACE2) was significantly greater in 38 patients with 
moderate COPD compared to 61 healthy controls but not to a group 7 patients with asthma 
or asthma COPD overlap (ACO) (1). Furthermore values for ACE2 expression in a 
heterogeneous group of 23 patients with obstructive airways disease (OAD) comprising 
either  COPD ,ACO or asthma not taking inhaled corticosteroids (ICS) were significantly 
higher compared to 56 controls but not to 25 patients with OAD taking ICS. 
The problem with interpreting these results in a heterogeneous group of patients with OAD is 
that ACE2 is upregulated in smokers  and in COPD but downregulated in asthma and atopy 
(2, 3). Furthermore assaying ACE2 mRNA only tells one half of the story with regards to 
entry of SARS-CoV-2 into lung tissue , since asthma and atopy are both associated with 
upregulation of  transmembrane protease serine 2 (TMPRSS2) in airway epithelial cells (3). 
In this regard  in induced sputum cells from asthma patients , ICS has been shown to exhibit 
suppressive effects ex vivo on both ACE2 and TMPRSS2 expression(4). 
Maes et al fail to point out the inhibitory in vitro effects of ICS on local and systemic 
production interleukin-6 (5, 6), this being the strongest predictor for impending respiratory 
failure in severe COVID-19 infection (7). Finally a more specific ICS suppressive effect on 
SARS-CoV-2 replication has been described with ciclesonide and mometasone furoate but 
not with budesonide ,beclomethasone or budesonide (8). 
Taken together we believe these observations reinforce the need for patients with 
eosinophilic asthma and COPD to continue taking their ICS containing controller therapy as 
that will provide optimal disease control and perhaps also confer protection against viral 
triggers perhaps including SARS-CoV-2 .
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